H.C. Wainwright lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $21 from $24 and keeps a Buy rating on the shares. The firm cites the company’s higher outer-year operating expenses for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Bets Big on Growth Pipeline
- Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
- Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
- Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
- AnaptysBio price target lowered to $93 from $95 at Piper Sandler